Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $150.3 million.

  • Amphastar Pharmaceuticals' Accumulated Expenses rose 2611.51% to $150.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $150.3 million, marking a year-over-year increase of 2611.51%. This contributed to the annual value of $126.5 million for FY2024, which is 8628.99% up from last year.
  • According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' Accumulated Expenses is $150.3 million, which was up 2611.51% from $124.7 million recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Accumulated Expenses peaked at $198.7 million during Q2 2023, and registered a low of $63.7 million during Q4 2022.
  • Its 5-year average for Accumulated Expenses is $101.5 million, with a median of $81.9 million in 2021.
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Accumulated Expenses surged by 19838.12% in 2023 and then crashed by 4995.72% in 2024.
  • Amphastar Pharmaceuticals' Accumulated Expenses (Quarter) stood at $67.3 million in 2021, then fell by 5.33% to $63.7 million in 2022, then grew by 6.57% to $67.9 million in 2023, then soared by 86.29% to $126.5 million in 2024, then increased by 18.78% to $150.3 million in 2025.
  • Its Accumulated Expenses stands at $150.3 million for Q3 2025, versus $124.7 million for Q2 2025 and $123.1 million for Q1 2025.